<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14</volume><submitter>Cairns EA</submitter><pubmed_abstract>&lt;b>Objective:&lt;/b> Evidence is accumulating that components of the &lt;i>Cannabis sativa&lt;/i> plant may have therapeutic potential in treating psychiatric disorders. Medicinal cannabis (MC) products are legally available for prescription in Australia, primarily through the Therapeutic Goods Administration (TGA) Special Access Scheme B (SAS-B). Here we investigated recent prescribing practices for psychiatric indications under SAS-B by Australian doctors. &lt;b>Methods:&lt;/b> The dataset, obtained from the TGA, included information on MC applications made by doctors through the SAS-B process between 1st November 2016 and 30th September 2022 inclusive. Details included the primary conditions treated, patient demographics, prescriber location, product type (e.g., oil, flower or capsule) and the general</pubmed_abstract><journal>Frontiers in pharmacology</journal><pagination>1142680</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10279775</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing.</pubmed_title><pmcid>PMC10279775</pmcid><pubmed_authors>Benson MJ</pubmed_authors><pubmed_authors>Macphail SL</pubmed_authors><pubmed_authors>Cohen R</pubmed_authors><pubmed_authors>Cairns EA</pubmed_authors><pubmed_authors>Mohan A</pubmed_authors><pubmed_authors>Sachdev PS</pubmed_authors><pubmed_authors>Bedoya-Perez MA</pubmed_authors><pubmed_authors>McGregor IS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing.</name><description>&lt;b>Objective:&lt;/b> Evidence is accumulating that components of the &lt;i>Cannabis sativa&lt;/i> plant may have therapeutic potential in treating psychiatric disorders. Medicinal cannabis (MC) products are legally available for prescription in Australia, primarily through the Therapeutic Goods Administration (TGA) Special Access Scheme B (SAS-B). Here we investigated recent prescribing practices for psychiatric indications under SAS-B by Australian doctors. &lt;b>Methods:&lt;/b> The dataset, obtained from the TGA, included information on MC applications made by doctors through the SAS-B process between 1st November 2016 and 30th September 2022 inclusive. Details included the primary conditions treated, patient demographics, prescriber location, product type (e.g., oil, flower or capsule) and the general</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2026-04-07T13:30:17.428Z</modification><creation>2025-02-19T04:30:34.836Z</creation></dates><accession>S-EPMC10279775</accession><cross_references><pubmed>37346297</pubmed><doi>10.3389/fphar.2023.1142680</doi></cross_references></HashMap>